CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 20, 2022 | Series B | $100M | 1 | — | — | Detail |